Emanera capsules 20mg №28

Packaging

28 pcs.

Mechanism of action

Emanera is an anti-ulcer agent - proton pump inhibitor, programa isomer of Omeprazole. Reduces the secretion of hydrochloric acid in the stomach by specific inhibition of the proton pump in the parietal cells. Being a weak base and passing into the active form in the acidic environment of the secretory tubules of the parietal cells of the gastric mucosa, it is activated and inhibits the proton pump - the enzyme H⁺-K⁺-Atp-azu. Inhibits both basal and stimulated secretion of hydrochloric (hydrochloric) acid. The effect occurs within 1 hour after oral administration of 20 mg or 40 mg. With daily use for 5 days at a dose of 20 mg 1 time / day., The average maximum concentration of hydrochloric acid after stimulation with pentagastrin is reduced by 90%.

Indications and usage

Gastroesophageal reflux disease: erosive reflux esophagitis (treatment), prevention of relapse in patients with cured esophagitis, symptomatic treatment of GERD.

As part of a combination therapy: Helicobacter pylori eradication, duodenal ulcer associated with Helicobacter pylori, prevention of peptic ulcer recurrence in patients with peptic ulcer,associated with Helicobacter pylori.

Contraindications

Lactation period, hypersensitivity to esomepromazole.

Dosage and administration

Is ingested. The dose is 20-40 mg 1 time / day. The duration of treatment depends on the indications, treatment regimen, effectiveness.

In severe liver failure, the maximum dose is 20 mg / day.

Adverse Effects

Often: headache, abdominal pain, diarrhea, flatulence, nausea, vomiting, constipation.

Seldom: dermatitis, pruritus, urticaria, dizziness, dry mouth.

If there are symptoms such as significant spontaneous weight loss, frequent vomiting, dysphagia, vomiting of blood or melena, as well as the presence (or suspicion) of a stomach ulcer, the possibility of malignant neoplasm should be excluded, since treatment with esomeprazole can lead to smoothing symptoms and, thus, delay the formulation of the correct diagnosis.

With prolonged therapy, the patient’s condition should be monitored regularly.

During treatment with proton pump inhibitors, gastrin plasma levels rise as a result of reduced intragastric secretion of hydrochloric acid. In patients taking proton pump inhibitors for a long time, the formation of glandular cysts in the stomach is more often noted. These phenomena are due to physiological changes as a result of inhibition of the secretion of hydrochloric acid.

It is believed that with simultaneous use may increase concentrations in the blood plasma and enhance the effects of imipramine, clomipramine, citalopram.

It is believed that with simultaneous use, it is possible to reduce plasma concentrations and the clinical efficacy of itraconazole and Ketoconazole.

With simultaneous use with Clarithromycin, a case of a significant increase in the AUC of esomeprazole due to the inhibition of its metabolism under the influence of clarithromycin is described.

With simultaneous use may increase concentrations in the blood plasma of diazepam and phenytoin, which, apparently, has no clinical significance.